

Supplemental Information

Figure S1: Union of the three ESC-related pathways and the PluriNet. Ingenuity IPA visualization of the 3 top ranked attract pathways in the Mueller dataset, and the overlay with the PluriNet gene list originally identified by the Mueller analyses as diagnostic of pluripotency.





Figure S2: Ingenuity network map of the three ESC-related pathways. Plurinet genes are highlighted in green. Ingenuity IPA visualization of the 3 top ranked attract pathways in the Mueller dataset, and the overlay with the Plurinet gene list originally identified by the Mueller analyses as diagnostic of pluripotency. This figure highlights the connectivity between members of the plurinet and attract pathways with literature-annotated edges.



Mar, JC et al, *attract*: A method for identifying core pathways that define cellular phenotypes. Supplemental information

Figure S3: Ingenuity IPA visualization of parts of the ESC-related networks cover developmental inputs that feed into the Oct4 and Nanog signaling networks. Plurinet genes are highlighted in green.




Figure S4: Synexpression groups for the ECM pathway identified using *attract*.






Figure S5: Synexpression groups for the oxidative phosphorylation pathway identified using *attract*.



Mar, JC et al, *attract*: A method for identifying core pathways that define cellular phenotypes. Supplemental information

Figure S6: Synexpression groups for the genes in Pathways in cancer, identified by GSEAlm as the most significant and most representative pathway.



Mar, JC et al, *attract*: A method for identifying core pathways that define cellular phenotypes. Supplemental information

Table S1: Overlap between KEGG pathways is as high as 74% in some of the significant pathways identified by attract.

| KEGG Pathway ID | 03010 | 4512 | 0190 | 4510 | 5016 | 4530 | 5012 | 4060 | 4514 | 5010 | 4080 | KEGG Pathway Name | Adjusted P-values |
|-----------------|-------|------|------|------|------|------|------|------|------|------|------|---|------------------------|
| 03010 | 91 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | Ribosome | 9.22×10^{-06} |
| 4512 | 0 | 45 | 0 | 37 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | ECM-receptor interaction | 7.62×10^{-04} |
| 0190 | 0 | 0 | 92 | 0 | 63 | 0 | 63 | 0 | 0 | 63 | 0 | Oxidative phosphorylation | 1.15×10^{-03} |
| 4510 | 0 | 37 | 0 | 137 | 0 | 21 | 0 | 7 | 2 | 8 | 0 | Focal adhesion | 1.72×10^{-03} |
| 5016 | 0 | 0 | 63 | 0 | 127 | 0 | 72 | 0 | 0 | 71 | 1 | Huntington's disease | 1.72×10^{-03} |
| 4530 | 0 | 0 | 0 | 21 | 0 | 86 | 0 | 0 | 12 | 0 | 0 | Tight junction | 2.71×10^{-03} |
| 5012 | 0 | 0 | 63 | 0 | 72 | 0 | 90 | 0 | 0 | 67 | 0 | Parkinson's disease | 1.55×10^{-02} |
| 4060 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 62 | 0 | 1 | 0 | Cytokine-cytokine receptor interaction | 2.18×10^{-02} |
| 4514 | 0 | 4 | 0 | 2 | 0 | 12 | 0 | 0 | 59 | 0 | 0 | Cell adhesion molecules (CAM) | 2.18×10^{-02} |
| 5010 | 0 | 0 | 63 | 8 | 71 | 0 | 67 | 1 | 0 | 120 | 1 | Alzheimer's disease | 3.37×10^{-02} |
| 4080 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 47 | Neuroactive ligand-receptor interaction | 3.78×10^{-02} |

Mar, JC et al, *attract*: A method for identifying core pathways that define cellular phenotypes. Supplemental information

Table S2: Ranked lists of over-represented KEGG pathways using DAVID for generated by applying a P-value cut-off of 1×10^{-15} , where the top twenty pathways are shown. The P-values were adjusted to control the false discovery rate, using the Benjamini-Hochberg correction method. Significant pathways (P-value < 0.05) have been colored orange in the table.

| ID | Pathway Name | Adjusted P-values |
|-------|--|-------------------|
| 04510 | Focal adhesion | 0.0016 |
| 05222 | Small cell lung cancer | 0.0293 |
| 04512 | ECM-receptor interaction | 0.0357 |
| 04530 | Tight junction | 0.0828 |
| 03030 | DNA replication | 0.3784 |
| 05221 | Acute myeloid leukemia | 0.3788 |
| 04142 | Lysosome | 0.3797 |
| 03040 | Spliceosome | 0.3499 |
| 05200 | Pathways in cancer | 0.3467 |
| 03410 | Base excision repair | 0.3244 |
| 05216 | Thyroid cancer | 0.3053 |
| 03018 | RNA degradation | 0.3964 |
| 05412 | Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 0.4258 |
| 05212 | Pancreatic cancer | 0.4258 |
| 05219 | Bladder cancer | 0.5099 |
| 00230 | Purine metabolism | 0.5410 |
| 04514 | Cell adhesion molecules (CAMs) | 0.7121 |
| 05213 | Endometrial cancer | 0.7237 |
| 05215 | Prostate cancer | 0.7194 |
| 04670 | Leukocyte transendothelial migration | 0.7194 |

Mar, JC et al, *attract*: A method for identifying core pathways that define cellular phenotypes. Supplemental information

Table S3: Ranked lists of over-represented KEGG pathways using DAVID for generated by applying a P-value cut-off of 1×10^{-20} , where the top twenty pathways are shown. The P-values were adjusted to control the false discovery rate, using the Benjamini-Hochberg correction method. Significant pathways (P-value < 0.05) have been colored orange in the table.

| ID | Pathway Name | Adjusted P-values |
|-------|--------------------------------------|-------------------|
| 04510 | Focal adhesion | 0.3709 |
| 04530 | Tight junction | 0.2950 |
| 04142 | Lysosome | 0.4069 |
| 04512 | ECM-receptor interaction | 0.4593 |
| 04514 | Cell adhesion molecules (CAMs) | 0.5522 |
| 05214 | Glioma | 0.8130 |
| 05219 | Bladder cancer | 0.7916 |
| 00450 | Selenoamino acid metabolism | 0.8122 |
| 05416 | Viral myocarditis | 0.7816 |
| 05222 | Small cell lung cancer | 0.8438 |
| 04810 | Regulation of actin cytoskeleton | 0.8373 |
| 05200 | Pathways in cancer | 0.8116 |
| 04722 | Neurotrophin signaling pathway | 0.7961 |
| 05215 | Prostate cancer | 0.8294 |
| 05213 | Endometrial cancer | 0.8169 |
| 04670 | Leukocyte transendothelial migration | 0.8109 |
| 00330 | Arginine and proline metabolism | 0.7996 |
| 03410 | Base excision repair | 0.8512 |
| 04012 | ErbB signaling pathway | 0.8791 |
| 00480 | Glutathione metabolism | 0.8685 |

Mar, JC et al, *attract*: A method for identifying core pathways that define cellular phenotypes. Supplemental information

Table S4: Ranked lists of over-represented KEGG pathways using DAVID for generated by applying a P-value cut-off of 1×10^{-25} , where the top twenty pathways are shown. The P-values were adjusted to control the false discovery rate, using the Benjamini-Hochberg correction method. Significant pathways (P-value < 0.05) have been colored orange in the table.

| ID | Pathway Name | Adjusted P-values |
|-------|--|-------------------|
| 05219 | Bladder cancer | 0.2647 |
| 04530 | Tight junction | 0.3611 |
| 05200 | Pathways in cancer | 0.7539 |
| 04514 | Cell adhesion molecules (CAMs) | 0.8849 |
| 04510 | Focal adhesion | 0.8497 |
| 04672 | Intestinal immune network for IgA production | 0.8833 |
| 00450 | Selenoamino acid metabolism | 0.8471 |
| 05130 | Pathogenic Escherichia coli infection | 0.8438 |
| 04142 | Lysosome | 0.8128 |
| 04540 | Gap junction | 0.8250 |
| 00460 | Cyanoamino acid metabolism | 0.8279 |
| 05416 | Viral myocarditis | 0.8827 |
| 00430 | Taurine and hypotaurine metabolism | 0.8809 |
| 04512 | ECM-receptor interaction | 0.9240 |
| 04670 | Leukocyte transendothelial migration | 0.9116 |
| 05410 | Hypertrophic cardiomyopathy (HCM) | 0.9190 |
| 00480 | Glutathione metabolism | 0.9134 |
| 05215 | Prostate cancer | 0.9255 |
| 05414 | Dilated cardiomyopathy | 0.9195 |
| 05213 | Endometrial cancer | 0.9138 |

Table S5: Degree of overlap between the lists of significantly differentially expressed genes generated from LIMMA (as inputs to DAVID) and the pathways identified by GSEA-ANOVA from *attract*. Two of the significantly enriched pathways that were identified by DAVID are highlighted in yellow; these two pathways demonstrate a higher percentage of overlap than most of the other pathways.

| KEGG Pathway Name | Number of Detected Genes | Overlap (%) with List1 [P-value < 1×10 ⁻¹⁵] | Significance of Overlap (P-value) | Overlap (%) with List2 [P-value < 1×10 ⁻²⁰] | Significance of Overlap (P-value) | Overlap (%) with List3 [P-value < 1×10 ⁻²⁵] | Significance of Overlap (P-value) |
|---|--------------------------|---|-----------------------------------|---|-----------------------------------|---|-----------------------------------|
| Ribosome | 91 | 8 | 0.999 | 2 | 0.993 | 0 | 0.949 |
| ECM-receptor interaction | 45 | 27 | 2.08×10 ⁻⁰⁹ | 12 | 0.000154 | 4 | 0.0137 |
| Oxidative phosphorylation | 92 | 10 | 0.992 | 3 | 0.977 | 1 | 0.798 |
| Focal adhesion | 137 | 63 | 1.31×10 ⁻¹¹ | 29 | 7.37×10 ⁻⁰⁶ | 9 | 0.0128 |
| Huntington's disease | 127 | 19 | 0.947 | 4 | 0.994 | 1 | 0.918 |
| Tight junction | 86 | 39 | 9.69×10 ⁻⁰⁸ | 21 | 8.56×10 ⁻⁰⁶ | 9 | 0.000400 |
| Parkinson's disease | 90 | 11 | 0.978 | 5 | 0.856 | 2 | 0.553 |
| Cytokine-cytokine receptor interaction | 62 | 28 | 4.68×10 ⁻⁰⁶ | 11 | 0.0108 | 5 | 0.0138 |
| Cell adhesion molecules (CAMs) | 59 | 32 | 3.82×10 ⁻⁰⁹ | 18 | 8.03×10 ⁻⁰⁷ | 7 | 0.000529 |
| Alzheimer's disease | 120 | 24 | 0.557 | 8 | 0.801 | 2 | 0.745 |
| Neuroactive ligand-receptor interaction | 47 | 20 | 0.000211 | 12 | 0.000249 | 5 | 0.00357 |
| Total List Size | | 2914 | | 1127 | | 362 | |

Mar, JC et al, *attract*: A method for identifying core pathways that define cellular phenotypes. Supplemental information

Table S6: Ranked list of pathways identified by GSEAIm where pathways reflect those that have the most significant changes between the ESC group and the neural progenitor cell lines. Pathway list is ranked first by the P-value and second by the number of detected genes annotated to the pathway and only the top twenty results are shown.

| KEGG Pathway ID | KEGG Pathway Name | P-value | Number of Detected Genes |
|------------------------|--------------------------------------|----------------|---------------------------------|
| 5200 | Pathways in cancer | 0.00019996 | 212 |
| 4010 | MAPK signaling pathway | 0.00019996 | 157 |
| 4810 | Regulation of actin cytoskeleton | 0.00019996 | 139 |
| 4510 | Focal adhesion | 0.00019996 | 137 |
| 4144 | Endocytosis | 0.00019996 | 126 |
| 4142 | Lysosome | 0.00019996 | 97 |
| 4910 | Insulin signaling pathway | 0.00019996 | 97 |
| 4062 | Chemokine signaling pathway | 0.00019996 | 95 |
| 4722 | Neurotrophin signaling pathway | 0.00019996 | 95 |
| 4360 | Axon guidance | 0.00019996 | 95 |
| 4666 | Fc gamma R-mediated phagocytosis | 0.00019996 | 71 |
| 4020 | Calcium signaling pathway | 0.00019996 | 68 |
| 4660 | T cell receptor signaling pathway | 0.00019996 | 66 |
| 4270 | Vascular smooth muscle contraction | 0.00019996 | 66 |
| 4670 | Leukocyte transendothelial migration | 0.00019996 | 65 |
| 4912 | GnRH signaling pathway | 0.00019996 | 64 |
| 5210 | Colorectal cancer | 0.00019996 | 63 |
| 4012 | ErbB signaling pathway | 0.00019996 | 63 |
| 5220 | Chronic myeloid leukemia | 0.00019996 | 62 |
| 4350 | TGF-beta signaling pathway | 0.00019996 | 62 |

Mar, JC et al, *attract*: A method for identifying core pathways that define cellular phenotypes. Supplemental information

Table S7: List of pathways from GSEAlm analysis ranked by pathway size. The dominance of most significant pathways is apparent in the top twenty pathways. Pathways with the most extreme significant P-value have been highlighted in yellow.

| KEGG Pathway ID | KEGG Pathway Name | P-value | Number of Detected Genes |
|-----------------|----------------------------------|-------------|--------------------------|
| 1100 | Metabolic pathways | 0.986402719 | 692 |
| 5200 | Pathways in cancer | 0.00019996 | 212 |
| 4010 | MAPK signaling pathway | 0.00019996 | 157 |
| 4810 | Regulation of actin cytoskeleton | 0.00019996 | 139 |
| 4510 | Focal adhesion | 0.00019996 | 137 |
| 5016 | Huntington's disease | 1 | 127 |
| 4144 | Endocytosis | 0.00019996 | 126 |
| 5010 | Alzheimer's disease | 0.00959808 | 120 |
| 3040 | Spliceosome | 1 | 111 |
| 4110 | Cell cycle | 1 | 110 |
| 4120 | Ubiquitin mediated proteolysis | 1 | 108 |
| 230 | Purine metabolism | 1 | 107 |
| 4310 | Wnt signaling pathway | 0.936612677 | 106 |
| 4142 | Lysosome | 0.00019996 | 97 |
| 4910 | Insulin signaling pathway | 0.00019996 | 97 |
| 4062 | Chemokine signaling pathway | 0.00019996 | 95 |
| 4722 | Neurotrophin signaling pathway | 0.00019996 | 95 |
| 4360 | Axon guidance | 0.00019996 | 95 |
| 4114 | Oocyte meiosis | 1 | 93 |
| 190 | Oxidative phosphorylation | 0.99480104 | 92 |